Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 36 clinical trials
The IPLA-OVCA Trial Intra-Peritoneal Local Anaesthetics in Ovarian Cancer

Surgery and chemotherapy combined constitute first line treatment in women with advanced ovarian cancer. The aim of surgery apart from staging is cytoreduction, i.e. surgical resection of tumour. Radical resection of all tumour visible by the naked eye followed by adjuvant chemotherapy is associated with best chance of prolonged survival. …

fallopian tube
ovarian cancer stage
cancer of the ovary
cytoreductive surgery
  • 30 Jan, 2021
  • 1 location
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian Fallopian Tube or Primary Peritoneal Cancer

This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned (recurrent) after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued …

platinum-based chemotherapy
primary peritoneal carcinoma
hormone therapy
  • 19 Sep, 2021
  • 212 locations
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.

renal function tests
debulking surgery
ovarian epithelial carcinoma
  • 19 Sep, 2021
  • 95 locations
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian Primary Peritoneal or Fallopian Tube Cancer LANCE Trial

This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant chemotherapy). MIS is a surgical procedure that uses small incision(s) and is intended to produce minimal blood …

  • 26 Jan, 2021
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune …

step 2
replacement therapy
hormone therapy
papillary serous adenocarcinoma
  • 19 Sep, 2021
  • 191 locations
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial enrolls participants for …

total bilirubin
peritoneal mesothelioma
gastrointestinal stromal tumor
desmoid tumors
  • 19 Sep, 2021
  • 818 locations
Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma

Endometrial Serous carcinoma (ESC) has similar molecular characteristics to high-grade serous ovarian carcinoma (HGSOC) and basal cell-like breast cancer, such as similar Chromosomal instability, somatic copy number variation profiles and somatic mutations. The clinical treatment of ESC also refers to the treatment model of HGSOC. The PARP inhibitor niraparib used …

  • 30 Jan, 2021
  • 1 location
Testing the Response to the Anti-cancer Drug Triapine in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

This early phase I trial investigates the response of the anti-cancer drug, triapine, in uterine cancers by using markers from tissue samples at the time of removal of the uterus, ovaries, and fallopian tubes (hysterectomy and bilateral salpingo-oophorectomy). Triapine may stop the growth of tumor cells by blocking some of …

  • 29 Aug, 2021
  • 1 location
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

This phase I/Ib trial identifies the side effects and best dose of abemaciclib when given together with olaparib in treating patients with ovarian cancer that responds at first to treatment with drugs that contain the metal platinum but then comes back within a certain period (recurrent platinum-resistant). Abemaciclib may stop …

  • 19 Sep, 2021
  • 5 locations
Olaparib and Entinostat in Patients With Recurrent Platinum-Refractory Resistant Ovarian Primary Peritoneal Fallopian Tube Cancers

This phase I/II trial studies the side effects and best dose of olaparib and entinostat and to see how well they work in treating patients with ovarian, primary peritoneal, or fallopian tube cancers that have come back or do not respond to platinum-based chemotherapy. Olaparib and entinostat may stop the …

platinum-based chemotherapy
recurrent disease
liver metastasis
serous cystadenocarcinoma
  • 24 Jul, 2021
  • 2 locations